Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT-660602 is an orally active chemokine receptor CXCR3 antagonist (IC50: 204 nM). ACT-660602 inhibits T cell migration and has shown significant effects in an in vivo model of acute lung injury. ACT-660602 can be used to study autoimmune diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | ACT-660602 is an orally active chemokine receptor CXCR3 antagonist (IC50: 204 nM). ACT-660602 inhibits T cell migration and has shown significant effects in an in vivo model of acute lung injury. ACT-660602 can be used to study autoimmune diseases. |
Molecular Weight | 534.48 |
Formula | C20H20F6N8OS |
CAS No. | 1646267-59-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ACT-660602 1646267-59-5 inhibitor inhibit